Atlas Trials

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Clinical trial NCT05019534 · UNKNOWN

Trial details

NCT number
NCT05019534
Sponsor
West China Hospital
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
BRAF V600E-mutated /MSS Metastatic Colorectal CancerVemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
Start date
2021-08-15
Primary completion
2022-08-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.